Microbial Cell Factories (Oct 2021)

Multivalent poultry vaccine development using Protein Glycan Coupling Technology

  • Marta Mauri,
  • Thippeswamy H. Sannasiddappa,
  • Prerna Vohra,
  • Ricardo Corona-Torres,
  • Alexander A. Smith,
  • Cosmin Chintoan-Uta,
  • Abi Bremner,
  • Vanessa S. Terra,
  • Sherif Abouelhadid,
  • Mark P. Stevens,
  • Andrew J. Grant,
  • Jon Cuccui,
  • Brendan W. Wren,
  • the Glycoengineering of Veterinary Vaccines Consortium

DOI
https://doi.org/10.1186/s12934-021-01682-4
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 26

Abstract

Read online

Abstract Background Poultry is the world's most popular animal-based food and global production has tripled in the past 20 years alone. Low-cost vaccines that can be combined to protect poultry against multiple infections are a current global imperative. Glycoconjugate vaccines, which consist of an immunogenic protein covalently coupled to glycan antigens of the targeted pathogen, have a proven track record in human vaccinology, but have yet to be used for livestock due to prohibitively high manufacturing costs. To overcome this, we use Protein Glycan Coupling Technology (PGCT), which enables the production of glycoconjugates in bacterial cells at considerably reduced costs, to generate a candidate glycan-based live vaccine intended to simultaneously protect against Campylobacter jejuni, avian pathogenic Escherichia coli (APEC) and Clostridium perfringens. Campylobacter is the most common cause of food poisoning, whereas colibacillosis and necrotic enteritis are widespread and devastating infectious diseases in poultry. Results We demonstrate the functional transfer of C. jejuni protein glycosylation (pgl) locus into the genome of APEC χ7122 serotype O78:H9. The integration caused mild attenuation of the χ7122 strain following oral inoculation of chickens without impairing its ability to colonise the respiratory tract. We exploit the χ7122 pgl integrant as bacterial vectors delivering a glycoprotein decorated with the C. jejuni heptasaccharide glycan antigen. To this end we engineered χ7122 pgl to express glycosylated NetB toxoid from C. perfringens and tested its ability to reduce caecal colonisation of chickens by C. jejuni and protect against intra-air sac challenge with the homologous APEC strain. Conclusions We generated a candidate glycan-based multivalent live vaccine with the potential to induce protection against key avian and zoonotic pathogens (C. jejuni, APEC, C. perfringens). The live vaccine failed to significantly reduce Campylobacter colonisation under the conditions tested but was protective against homologous APEC challenge. Nevertheless, we present a strategy towards the production of low-cost “live-attenuated multivalent vaccine factories” with the ability to express glycoconjugates in poultry.

Keywords